Abstract Details

Title ITP Following Treatment of Multiple Sclerosis Patients with Alemtuzumab in CAMMS223: Case Reports and Risk Management Plan Implementation

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 004

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Herman C. Sullivan, MD	The institution of Dr. Sullivan has received research support from Novartis. The institution of Dr. Sullivan has received research support from Sanofi.
Robert J. Murphy, MD (Neurology Consultants of Kansas)	No disclosure on file
	No disclosure on file

��ɫ��